Paper Details

  1. Home
  2. Paper Details

Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial.

Author: , BeckerStephen L, BellosNicholaos C, BergerDaniel, ChengAndrew, CoakleyDion F, MillerMichael D, PieroneGerald, PozniakAnton L, SquiresKathleen, SteinhartCorklin R, TooleJohn J, WulfsohnMichael

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tenofovir DF significantly reduced HIV-1 RNA levels in treatment-experienced patients with suboptimal viral suppression and had a safety profile similar to placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Resistance to antiretroviral agents remains a leading cause of treatment failure for patients infected with HIV-1. OBJECTIVE: To describe the efficacy and safety of tenofovir disoproxil fumarate (tenofovir DF) compared with placebo in patients with detectable viral replication despite c...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.7326/0003-4819-139-5_part_1-200309020-00006

データ提供：米国国立医学図書館（NLM）

Tenofovir Disoproxil Fumarate: A New Hope for HIV-1 Resistance

HIV-1 infection remains a global health challenge, with drug resistance often leading to treatment failure. This study focuses on tenofovir disoproxil fumarate (tenofovir DF), a promising new drug that targets HIV-1 even in the presence of resistance. It's like finding a hidden oasis in the desert of HIV-1 treatment, providing a vital source of hydration and hope.

The researchers conducted a randomized controlled trial to evaluate the efficacy and safety of tenofovir DF in patients with HIV-1 resistance. They discovered that tenofovir DF significantly reduced viral load in patients who had not responded well to previous treatments. It's like the drug was able to carve out a new path through the desert of viral resistance, leading to improved outcomes.

Tenofovir DF: A Powerful Weapon in the Fight Against HIV-1

The study highlights the potential of tenofovir DF as a valuable addition to the arsenal of HIV-1 treatment options. Its efficacy in combating drug-resistant strains is a significant development, offering new hope to patients struggling with persistent viral replication. This discovery could potentially change the landscape of HIV-1 treatment, leading to more successful and long-lasting outcomes.

Staying Hydrated in the Desert of HIV-1

The fight against HIV-1 is an ongoing battle, and this study offers a beacon of hope. The development of drugs like tenofovir DF that can combat resistant strains is crucial for improving the lives of individuals living with HIV-1. It's like discovering a new water source in the desert, providing vital sustenance and helping people thrive in the challenging environment of HIV-1 infection.

Dr.Camel's Conclusion

This study demonstrates the effectiveness of tenofovir DF in reducing viral load in HIV-1-infected patients with resistance to other antiretroviral agents. This breakthrough holds immense promise for improving HIV-1 treatment outcomes and offers a beacon of hope for patients facing the challenges of drug resistance.

Date :
  1. Date Completed 2003-09-30
  2. Date Revised 2022-03-18
Further Info :

Pubmed ID

12965939

DOI: Digital Object Identifier

10.7326/0003-4819-139-5_part_1-200309020-00006

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.